Prediction evidence

Quoting · 19 Aug 2026, 10:55 UTC · context given to the AI

MERCK $MRK AND MODERNA $MRNA JUST HIT THE FIRST POSITIVE PHASE 3 RESULT EVER FOR A PERSONALIZED CANCER VACCINE Their Phase 3 INTerpath-001 trial found that "intismeran autogene, an mRNA therapy custom-built from each patient's own tumor mutations, combined with Merck's KEYTRUDA, significantly improved recurrence-free survival and distant metastasis-free survival versus KEYTRUDA alone in patients with completely resected stage IIB-IV melanoma." This is the first Phase 3 readout ever for an individualized neoantigen therapy, and the first Phase 3 study to beat KEYTRUDA alone as a standard-of-care adjuvant treatment for resected melanoma. Merck and Moderna will present full data at an upcoming medical meeting and begin talking with regulators about filing submissions.